| Literature DB >> 19439487 |
Takuo Ogihara1, Takashi Kano, Tamae Wagatsuma, Sho Wada, Hikaru Yabuuchi, Shigeki Enomoto, Kaori Morimoto, Yoshiyuki Shirasaka, Shoko Kobayashi, Ikumi Tamai.
Abstract
Oseltamivir, an ester-type prodrug of the neuraminidase inhibitor [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), has been developed for the treatment of A and B strains of the influenza virus but has neuropsychiatric and other side effects. In this study, we characterized the transport across intestinal epithelial cells and the absorption of oseltamivir in rats. Uptake by Caco-2 cells (human carcinoma cell line) and HeLa cells transfected with peptide transporter 1 (HeLa/PEPT1) was time- and temperature-dependent and was inhibited by typical PEPT1 inhibitors such as glycyl-sarcosine (Gly-Sar). The uptake by Caco-2 cells and HeLa/PEPT1 was saturable, with similar K(m) values. Oseltamivir absorption in adult rats was greatly reduced by simultaneous administration of milk, casein, or Gly-Sar. Furthermore, the plasma and brain concentrations of oseltamivir were higher in fasting than in nonfasting rats after oral administration. These results suggest that oseltamivir is a substrate of PEPT1 and that PEPT1 is involved in its intestinal absorption.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19439487 DOI: 10.1124/dmd.109.026922
Source DB: PubMed Journal: Drug Metab Dispos ISSN: 0090-9556 Impact factor: 3.922